Julian McLeod, PA
Medical · Rocky Mount, NCNPI 1003898107
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.6% of the total across 509 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 43 manufacturers, the largest accounting for just 17.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $2,356 and has fallen 51.7% since, to $1,138 in 2025. Among medical clinicians in NC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 509 payments — averaging $17.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- AstraZeneca$1K
- Amgen$1K
- Lilly USA, LLC$978
- AbbVie$733
- Boehringer Ingelheim$337
- plus $3K from 37 others
What the payments were for
- Food & beverage$9,091100%
- Education$370%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,127 in reported general payments places this provider in the 90th percentile of 878 medical providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prolastin CAlpha-1-Proteinase Inhibitor | 11 | $152,074 |
| FarxigaDapagliflozin Propanediol | 146 | $124,612 |
| JardianceEmpagliflozin | 113 | $101,842 |
| OzempicSemaglutide | 77 | $86,784 |
| RybelsusSemaglutide | 78 | $83,419 |
| EliquisApixaban | 104 | $83,390 |
| MounjaroTirzepatide | 32 | $54,984 |
| TrulicityDulaglutide | 34 | $34,590 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 42 | $31,780 |
| Tresiba Flextouch U-200Insulin Degludec | 30 | $28,146 |
| LinzessLinaclotide | 31 | $26,254 |
| XareltoRivaroxaban | 19 | $25,020 |
| TradjentaLinagliptin | 26 | $19,912 |
| KerendiaFinerenone | 24 | $15,506 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 18 | $14,166 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $1,624 | $170,203155 claims |
| Grifols USA, LLCProlastin C | $136 | $152,07411 claims |
| AstraZenecaFarxiga, Brilinta | $1,214 | $129,740158 claims |
| Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr | $337 | $128,971151 claims |
| Lilly USA, LLCMounjaro, Trulicity | $978 | $89,57566 claims |
| PfizerEliquis | $245 | $83,390104 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $239 | $41,75857 claims |
| AbbVieLinzess, Synthroid | $733 | $27,96959 claims |
| BayerKerendia | $262 | $15,50624 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $106 | $14,16618 claims |
| MerckJanuvia | $320 | $12,36914 claims |
| Astellas Pharma US IncMyrbetriq | $26 | $5,41312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 878 medical providers in North Carolina.
Other medical in Rocky Mount
- Grace McLaurinHickory$553K
- Joel ThompsonCharlotte$265K
- Virginia JethroCary$213K
- Payal Soni-PatelAsheville$76K
- William JarrettElkin$59K
- Amanda ZimmermanWinston Salem$48K
- David TaylorMorehead City$40K
- Katherine CardSalisbury$39K
- John RobbinsWinston Salem$26K
- Ashley TipperStatesville$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.